13 withdrawn. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Withdrawn 13 |
Follow Neurodevelopmental Disorders: new trials by email Literature Review of Neurodevelopmental Disorders trials Research Report on Neurodevelopmental Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities Valbenazine Oral Capsule - Tardive Dyskinesia, Intellectual Disability | Phase 4 | Withdrawn | Stephen Ruedrich | 2025-01-01 | 2024-10-24 | |
| Efficacy of Biofeedback in the Treatment of Tic Disorder Drug Aripiprazole, biofeedback - Tic Disorders | Phase 4 | Withdrawn | Children's Hospital of Fudan University | 2024-06-01 | 2025-01-20 | |
| Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD Methylphenidate, Placebo - ADHD | Phase 4 | Withdrawn | Johns Hopkins University | 2024-04-16 | 2024-03-15 | |
| ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder ADZENYS XR-ODT, Placebo Oral Tablet - Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Aytu BioPharma, Inc. | 2019-05-01 | 2025-10-03 | |
| A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. methylphenidate HCl ERCT, Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Pfizer | 2018-10-31 | 2018-11-01 | |
| Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. methylphenidate HCl ERCT - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Withdrawn | Pfizer | 2018-09-25 | 2018-11-01 | |
| A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT), Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Pfizer | 2018-09-19 | 2018-11-01 | |
| Adaptive Response to Intervention (RTI) for Students With ADHD Tier 1 Classroom Management, Daily Report Card (DRC), Enhanced DRC (DRC-E) - Attention Deficit Disorder With Hyperactivity | Phase 4 | Withdrawn | Florida International University | 2018-05-14 | 2025-08-07 | |
| Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging OROS-MPH - ADHD | Phase 4 | Withdrawn | Massachusetts General Hospital | 2015-04-01 | 2015-04-28 | |
| Effect of Methylphenidate on Connectivity Methylphenidate, Placebo - Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Iris Sommer | 2013-04-01 | 2014-02-26 | |
| Multidimensional Treatment Foster Care for Adolescents Multidimensional Treatment Foster Care, Treatment as usual - Adolescent Behaviour, Family Functioning | Phase 4 | Withdrawn | VIVE - The Danish Center for Social Science Research | 2012-11-01 | 2013-11-07 | |
| Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate methylphenidate HCl (Concerta), Placebo - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Withdrawn | University of Pittsburgh | 2010-04-01 | 2012-08-24 | |
| Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Substance Use Disorder | Phase 4 | Withdrawn | Massachusetts General Hospital | 2013-03-05 |
Attention Deficit Disorder with Hyperactivity (10) · Caregiver Burden (1) · Conduct Disorder (1) · Developmental Disabilities (1) · Intellectual Disability (1) · Movement Disorders (1) · Substance-Related Disorders (1) · Tardive Dyskinesia (1) · Tic Disorders (1)
Mental Disorders (13) · Attention Deficit and Disruptive Behavior Disorders (11) · Central Nervous System Diseases (2) · Nervous System Diseases (2) · Behavior (1) · Behavioral Symptoms (1) · Chemically-Induced Disorders (1) · Dyskinesia, Drug-Induced (1) · Dyskinesias (1) · Movement Disorders (1) · Neurobehavioral Manifestations (1) · Neurologic Manifestations (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Methylphenidate (4) · Amphetamine (1) · Atomoxetine Hydrochloride (1) · Biofeedback, Psychology (1) · Central Nervous System Stimulants (1) · Therapeutics (1) · valbenazine (1)
Pfizer (3) · Massachusetts General Hospital (2) · Aytu BioPharma, Inc. (1) · Children's Hospital of Fudan University (1) · Florida International University (1) · Iris Sommer (1) · Johns Hopkins University (1) · Stephen Ruedrich (1) · University of Pittsburgh (1) · VIVE - The Danish Center for Social Science Research (1)
United States (7) · China (1) · Denmark (1) · Netherlands (1)
Ann Childress, MD (1) · Carolyn R Sikes, PhD (1) · Iris EC Sommer, Prof, Dr. (1) · Kristin Bigos, PhD (1) · Mette Deding (1) · Oscar G Bukstein, MD, MPH (1) · Stephen Ruedrich, MD (1) · Thomas Spencer, MD (1) · Timothy Wilens, MD (1)
K24DA016264 (1)